Researchers studied the relationship between lymphovascular invasion and adverse outcomes in patients with cutaneous squamous cell carcinoma.

People with locally advanced head and neck squamous cell carcinoma (HNSCC) now have a new treatment option that could extend their lives with fewer side effects. The U.S. Food and Drug Administration ...

The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc ...

The KEYNOTE-689 trial randomized 714 patients with newly diagnosed stage 3 or stage 4A head and neck squamous cell cancer to receive either pembrolizumab before (called neoadjuvant), during and ...

Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma prior to surgery. ClinicalTrials.gov. Updated October 26, 2022.

The receptor for the complement component C5a may be a useful therapeutic target for cases of cutaneous squamous cell carcinoma (cSCC), according to a new report. 1 The study, published in the ...

Traws Pharma published key clinical efficacy data for rigosertib in patients with RDEB-associated squamous cell carcinoma. What is rigosertib being evaluated for?

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...

Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts). This is an ASCO Meeting Abstract ...

Survival for head and neck squamous cell carcinoma treated with versus without neoadjuvant systemic therapy: A national propensity score–matched analysis.. If you have the appropriate software ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...